Inactive Instrument

Company Seagen Inc.

Equities

SGEN

US81181C1045

Biotechnology & Medical Research

Business Summary

Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit :

- ventes de produits (87%) ;

- royalties (8,4%) ;

- revenus issus d'accords de collaboration et de licence (4,6%).

Number of employees: 3,256

Managers

Managers TitleAgeSince
President - Dec. 13
Chief Tech/Sci/R&D Officer 57 -
Chief Tech/Sci/R&D Officer - -
Investor Relations Contact - 20-11-30
Corporate Officer/Principal - 21-11-30
Corporate Officer/Principal - 23-01-31
Corporate Officer/Principal 52 10-12-31
Human Resources Officer - -

Members of the board

Members of the board TitleAgeSince
Director/Board Member - Dec. 13
Director/Board Member 55 Dec. 13

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 188,662,672 187,331,068 ( 99.29 %) 0 99.29 %

Company contact information

Seagen Inc.

21823 30th Drive South East

98021, Bothell

+

http://www.seagen.com
address Seagen Inc.(SGEN)